Research programme: tubulin polymerisation inhibitors - EntreMed

Drug Profile

Research programme: tubulin polymerisation inhibitors - EntreMed

Alternative Names: 3,3-Diarylacrylonitriles as tubulin polymerisation inhibitors - EntreMed; CC 4089; CC 5079; ENMD 1420; ENMD 1427; ENMD 1916; Tubulin polymerisation inhibitors - Celgene/EntreMed

Latest Information Update: 19 Dec 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Corporation
  • Developer EntreMed
  • Class Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 19 Dec 2008 Discontinued - Preclinical for Cancer in USA (PO)
  • 09 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the Cancer pharmacodynamics section
  • 06 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the pharmacokinetics and Cancer pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top